Fig. 1

Box Plot analysis illustrates central macular thickness in μm in eyes prior to treatment, at switch follow-up visit after treatment with bevacizumab (grey background) and at final follow-up visit after treatment with aflibercept (left side) and after treatment with ranibizumab (right side). The ordinate shows central macular thickness in μm for eyes at baseline visit prior to treatment (left box), at switch follow-up visit after treatment with bevacizumab (middle) and at final follow-up visit after treatment with aflibercept or ranibizumab (right box) shown on the abscissa. Statistically significant results (pairwise comparison Wilcoxon test, p < 0.05) are marked with an asterisk. Note that for AG there was a statistically significant reduction of mean central macular thickness compared at baseline and after aflibercept treatment (p = 0.0001) whereas for RG there was no statistically significant difference between baseline and final follow-up visit (p = 0.67)